ABG Innovation Capital Partners III’s Castle Biosciences CSTL Stock Holding History

ABG Innovation Capital Partners III’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-36,747	Closed	-$736K	–	2
2025 Q1	$736K	Hold	36,747	–	–	91.94%	1
2024 Q4	$979K	Hold	36,747	–	–	90.45%	1
2024 Q3	$1.05M	Hold	36,747	–	–	93.29%	1
2024 Q2	$800K	Buy	36,747 +3,121	+9%	+$69.5K	93.07%	1
2024 Q1	$745K	Sell	33,626 -3,121	-8%	-$67.9K	89.54%	1
2023 Q4	$793K	Buy	36,747 +3,121	+9%	+$54.9K	88.14%	1
2023 Q3	$568K	Hold	33,626	–	–	77.21%	1
2023 Q2	$461K	Hold	33,626	–	–	63%	1
2023 Q1	$764K	Hold	33,626	–	–	70.27%	1
2022 Q4	$792K	Hold	33,626	–	–	60.43%	1
2022 Q3	$877K	Hold	33,626	–	–	59.46%	1
2022 Q2	$738K	Buy	+33,626	New	+$781K	54.91%	1

Other funds holding CSTL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Allianz Asset Management Munich, Germany $112B AUM 36.28% 1-Year Est. Return

ABG Innovation Capital Partners III's CSTL Position: Q2 2025 in Review

ABG Innovation Capital Partners III sold out of Castle Biosciences (CSTL) in Q2 2025, closing a stake of 36,747 shares — an estimated $736K sold.

ABG Innovation Capital Partners III first reported a position in CSTL in Q2 2022 and held it in 12 quarters. The position peaked at $1.05M in Q3 2024. 152 funds tracked by Wall St. Rank hold CSTL as of Q2 2025.

ABG Innovation Capital Partners III reported no remaining Castle Biosciences position as of Q2 2025 after selling out during the quarter.
ABG Innovation Capital Partners III sold 36,747 Castle Biosciences shares in Q2 2025, an estimated $736K.
ABG Innovation Capital Partners III first reported a position in Castle Biosciences in Q2 2022 and held it in 12 quarters.
ABG Innovation Capital Partners III's Castle Biosciences position peaked at $1.05M in Q3 2024.
152 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2025.

Based on ABG Innovation Capital Partners III's 13F filing for Q2 2025, filed 14 Aug 2025.